JP2002521004A - ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用 - Google Patents

ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用

Info

Publication number
JP2002521004A
JP2002521004A JP2000559140A JP2000559140A JP2002521004A JP 2002521004 A JP2002521004 A JP 2002521004A JP 2000559140 A JP2000559140 A JP 2000559140A JP 2000559140 A JP2000559140 A JP 2000559140A JP 2002521004 A JP2002521004 A JP 2002521004A
Authority
JP
Japan
Prior art keywords
app
hslon
complex
derivative
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000559140A
Other languages
English (en)
Japanese (ja)
Inventor
クリシュナン ナンダバラン，
メイジア ヤン，
ビンセント ピーター シュルズ，
Original Assignee
キュラゲン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラゲン コーポレイション filed Critical キュラゲン コーポレイション
Publication of JP2002521004A publication Critical patent/JP2002521004A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000559140A 1998-07-10 1999-07-08 ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用 Withdrawn JP2002521004A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11334898A 1998-07-10 1998-07-10
US09/113,348 1998-07-10
PCT/US1999/015592 WO2000002911A2 (fr) 1998-07-10 1999-07-08 INTERACTION DE PRECURSEUR DE LA PROTEINE BETA-AMYLOIDE HUMAINE (β-APP) ET DE PROTEINE HUMAINE DU TYPE LON-PROTEASE (HsLON)

Publications (1)

Publication Number Publication Date
JP2002521004A true JP2002521004A (ja) 2002-07-16

Family

ID=22348923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000559140A Withdrawn JP2002521004A (ja) 1998-07-10 1999-07-08 ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用

Country Status (5)

Country Link
EP (1) EP1095154A2 (fr)
JP (1) JP2002521004A (fr)
AU (1) AU4869399A (fr)
CA (1) CA2332625A1 (fr)
WO (1) WO2000002911A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379620B1 (en) 1998-11-16 2002-04-30 Barry M. Tydings Assaying device and method for in field urinalysis
WO2001073057A1 (fr) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. Nouvelle molecule du type atpase appelee 19053 et ses utilisations
CN1315402A (zh) * 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
CN1323833A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人淀粉类前体蛋白结合蛋白51和编码这种多肽的多核苷酸
DK1456380T3 (da) 2001-11-02 2012-07-30 Giuliani Int Ltd SMAD7-inhibitorer til behandling af CNS-sygdomme
US6805838B2 (en) 2002-03-04 2004-10-19 Barry M. Tydings Assaying device and method for in field urinalysis
EP1572937B1 (fr) * 2002-04-09 2012-02-08 The Scripps Research Institute Polypeptides hybrides a greffe de motif structural et utilisations de ceux-ci
AU2003280420A1 (en) 2002-06-26 2004-01-19 Yale University Modulators and modulation of the interacton between rgm and neogenin
WO2004030524A2 (fr) 2002-10-03 2004-04-15 Pr Pharmaceuticals Traitement de l'autisme et de troubles similaires
EP2053409A1 (fr) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Marqueurs spécifiques du syndrome métabolique
WO2007039256A2 (fr) 2005-09-30 2007-04-12 Abbott Gmbh & Co. Kg Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102656190A (zh) 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
WO2011083147A1 (fr) 2010-01-08 2011-07-14 Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène
WO2011131626A1 (fr) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 code pour l'activité alkylglycérol monooxygénase dépendante de la tétrahydrobioptérine
IL305223A (en) 2012-01-27 2023-10-01 Abbvie Inc The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
EP3917620A4 (fr) * 2019-02-01 2023-02-08 Avrobio, Inc. Compositions et procédés de traitement de troubles neurocognitifs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3702789A1 (de) * 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins

Also Published As

Publication number Publication date
CA2332625A1 (fr) 2000-01-20
WO2000002911A3 (fr) 2001-01-18
EP1095154A2 (fr) 2001-05-02
WO2000002911A2 (fr) 2000-01-20
AU4869399A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
US5977311A (en) 53BP2 complexes
JP2002521004A (ja) ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用
JP4580618B2 (ja) 神経変性疾患におけるタンパク質凝集に関する材料および方法
JP2002510490A (ja) Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
JP2002526099A (ja) Ｎｌｋ１−相互作用タンパク質
JP2006508659A (ja) Ｃｉｚ１複製タンパク質
JP2001523455A (ja) Ｃｄｋ２タンパク質およびｃｄｋ２タンパク質複合体
AU770000B2 (en) Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof
JP2002517998A (ja) ｐ２７（ＫＩＰ１）のＦＫＢＰ−１２との相互作用
JP5158602B2 (ja) 心筋細胞の分化制御を司る脱リン酸化酵素
JP2003189883A (ja) 新規ユビキチン特異プロテアーゼ
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
US7402406B2 (en) Methods of evaluating phosphatase inhibitors
US20140234321A1 (en) Hunk, a snf1-related kinase essential for mammary tumor metastasis
JPWO2002064770A1 (ja) 新規スカベンジャー受容体クラスａ蛋白質
JP4375960B2 (ja) 生体代謝の修飾
JP2005511660A6 (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
JP2005511660A (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
WO2003048196A2 (fr) Moyens et procedes permettant de diagnostiquer et de traiter des malformations cranio-faciales
JPH10234378A (ja) ミオシン軽鎖結合サブユニット類縁タンパク質およびその遺伝子
JP2006519757A (ja) エネルギー恒常性の調節に関与するタンパク質
JPWO2002051999A1 (ja) 新規アトピー性皮膚炎関連遺伝子及び蛋白質
AU3291799A (en) Retinoblastoma protein complexes and retinoblastoma interacting proteins
JP2002533062A5 (fr)

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20061003